A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
NCT ID: NCT04195373
Last Updated: 2020-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2020-11-23
2020-11-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At least 15 patients will be enrolled. Patients will be randomized to different treatment groups: all patients will receive intra-tumoral TMV-018 on four visits and additionally 5-FC and/or anti-PD-1 treatment. All adverse events will be documented and analyzed for the primary safety endpoint. Blood and tumor samples will be collected up to day 72 to determine the safety, tolerability and immunogenicity of the treatment. The patients will be followed-up for another two years to determine long-term safety.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TMV-018 + 5-FC
Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC.
TMV-018 + 5-FC
TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase"; 1E+06 TCID50 to 1E+08 TCID50 per dose.
5-FC: 150 mg/kg/day for 2 days during each treatment.
TMV-018 + anti-PD-1 inhibitor
Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with an anti-PD-1 Inhibitor.
TMV-018 + anti-PD-1
TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase"; 1E+06 TCID50 to 1E+08 TCID50 per dose.
Anti-PD-1 inhibitor dose according to its SMPC.
TMV-018 + 5-FC + anti-PD-1 inhibitor
Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC and an anti-PD-1 Inhibitor.
TMV-018 + 5-FC + anti-PD-1
TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase"; 1E+06 TCID50 to 1E+08 TCID50 per dose.
5-FC: 150 mg/kg/day for 2 days during each treatment cycle.
Anti-PD-1 Inhibitor: dose according to its SMPC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TMV-018 + 5-FC
TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase"; 1E+06 TCID50 to 1E+08 TCID50 per dose.
5-FC: 150 mg/kg/day for 2 days during each treatment.
TMV-018 + anti-PD-1
TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase"; 1E+06 TCID50 to 1E+08 TCID50 per dose.
Anti-PD-1 inhibitor dose according to its SMPC.
TMV-018 + 5-FC + anti-PD-1
TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase"; 1E+06 TCID50 to 1E+08 TCID50 per dose.
5-FC: 150 mg/kg/day for 2 days during each treatment cycle.
Anti-PD-1 Inhibitor: dose according to its SMPC.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. At least 18 years of age on the day of signing the informed consent.
3. Histologically confirmed diagnosis of advanced, metastatic tumors of the gastrointestinal tract (stage IV)
4. Before enrollment (i.e., at least 4 weeks before study treatment): Prior chemotherapy, targeted therapy, radiotherapy, to treat cancer or major surgery have to be stopped at least 4 weeks prior to enrolment.
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and life expectancy ≥ 3 months as assessed during screening period.
6. All female participants of childbearing potential, defined as all woman physiologically capable of becoming pregnant, must have a negative pregnancy test at screening.
7. Willingness not to become pregnant or to father a child during study participation by practicing reliable methods of contraception.
8. Patient must have exhausted all current standard therapy lines in the target cancer indications
9. Adequate organ function as determined by laboratory parameters.
Exclusion Criteria
2. Patients with brain metastases.
3. Patients with poorly controlled hypertension, or cardiovascular and cerebrovascular diseases with clinical significance.
4. Patients with other serious organic diseases or mental disorders.
5. Patients with active infections, which cannot be controlled with drugs or have potential impact on treatment, or patients with concurrent opportunistic infections.
6. Patients exhibiting evidence of clinically significant immunosuppression such as primary or acquired immunodeficiency state
7. Pregnancy (positive pregnancy test at screening or before end of study participation) or lactation at screening or planning to become pregnant before completion of study participation.
8. Males who have sex to conceive a child / who want to donate semen, during the study and up to 4 months after the last dose of TMV-018, 5-FC or pembrolizumab.
9. Males and female subjects of childbearing potential who are unwilling to use double barrier methods of effective contraception
10. Patients with an impaired renal function (creatinine clearance ≤ 40 mL/min).
11. Patients currently or recently (\< 2 months) taking fluconazole, itraconazole, clotrimazole troches, itraconazole, amphotericin or other oral anti-fungal medications.
12. Patients with contraindications for treatment with flucytosine (5-FC)
13. Known hypersensitivity to 5-FU, known deficiency in dihydropyrimidine dehydrogenase (DPD)
14. Known hypersensitivity to pembrolizumab, its excipients, or other monoclonal antibody.
15. Severe immune-related adverse reactions from treatment with pembrolizumab, defined as any grade 4 toxicity or grade 3 toxicity requiring corticosteroid treatment (\> 10 mg/day prednisone or equivalent) for greater than 12 weeks.
16. History or evidence of symptomatic autoimmune diseases.
17. Other medical condition or laboratory abnormality that in the judgment of the Investigator may increase the risk associated with study participation or may interfere with interpretation of study results.
18. History of severe systemic reaction or side-effect after a measles vaccination.
19. Subjects who continue to experience \> grade 1 Common Terminology Criteria for Adverse Events (CTCAE) toxicity due to cancer therapy within 4 weeks prior to enrollment will not be eligible.
20. Use of anti-cancer treatments within 4 weeks of TMV-018 treatment start.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assign Data Management and Biostatistics GmbH
OTHER
Optimapharm
INDUSTRY
Themis Bioscience GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ulrich Lauer, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Tuebingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Bonn
Bonn, , Germany
University Hospital Tübingen
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMV-018-101
Identifier Type: -
Identifier Source: org_study_id